How soon after starting Depakote do period changes show up?

In the STEP-BD study, irregular periods always began within 12 months of starting valproate. That makes the first year a key time to track your cycle. Tell your prescriber about any missed or very irregular periods.

Does Depakote cause cysts on the ovaries?

The label lists polycystic ovary disease as a reported reaction, and an epilepsy study found polycystic ovaries in 43% of women on valproate alone. But a 2016 meta-analysis in bipolar disorder found no clear rise in polycystic ovary appearance on ultrasound alone. The stronger signals were irregular periods and high androgens.

Is lamotrigine less likely to cause PCOS than valproate?

A 2023 network meta-analysis ranked valproate highest and lamotrigine lowest for PCOS risk among four anticonvulsant mood stabilizers. In STEP-BD, women on lithium or other anticonvulsants had a 1.4% rate of the PCOS pattern. Each medicine has its own risks, so the choice depends on your full history.

What symptoms should I report while taking Depakote?

Report missed or irregular periods, new hair on the face or body, worsening acne, scalp hair thinning, or fast weight gain. These can be signs of high androgen levels. Your prescriber may check hormone levels or refer you to a gynecologist or endocrinologist.

Should men worry about reproductive side effects from Depakote?

The label also lists male reproductive effects, including decreased sperm count, abnormal sperm, and male infertility. Men who plan to have children can raise this with their prescriber. This article focuses on effects in women.

Can Depakote Cause PCOS or Irregular Periods in Women?

The short answer: Yes, it can. Depakote (divalproex, a form of valproate) lists irregular menses, hyperandrogenism, and polycystic ovary disease among reported side effects in its FDA label. In the largest US study in bipolar disorder, 10.5% of women on valproate developed irregular periods with high androgen signs, compared with 1.4% on other mood stabilizers. Some of these changes eased after valproate was stopped. Talk to your prescriber before you change anything.

What does the Depakote label say about periods and PCOS?

The Depakote prescribing information on DailyMed has an endocrine list of adverse reactions. It names irregular menses, secondary amenorrhea (periods that stop), hyperandrogenism, hirsutism, elevated testosterone, and polycystic ovary disease. It also lists weight gain under metabolism and nutrition.

The label does not give a rate for these effects. They appear in a list of reactions reported with valproate, not in the placebo-controlled mania trial table. So the label tells you the effect is real enough to warn about. For numbers, you need the research studies below.

How common are PCOS features in women with bipolar disorder on valproate?

The best US data come from STEP-BD (the Systematic Treatment Enhancement Program for Bipolar Disorder). Researchers screened 300 women aged 18 to 45 at 16 sites. They used a set definition: oligoamenorrhea (few or absent periods) plus hyperandrogenism (hirsutism, acne, male-pattern hair loss, or high androgen levels).

The results, published in Biological Psychiatry in 2006, were clear:

9 of 86 women on valproate (10.5%) developed the pattern.
2 of 144 women on lithium or another anticonvulsant (1.4%) did.
The relative risk was 7.5.
In every case, the irregular periods began within 12 months of starting valproate.

Later reviews agree. A 2016 meta-analysis in women with bipolar disorder found higher odds of PCOS (odds ratio 6.74), menstrual disorders (1.81), and hyperandrogenism (2.02) with valproate. Testosterone levels were also higher. A 2023 network meta-analysis compared four anticonvulsant mood stabilizers. Valproate ranked highest for PCOS risk, and lamotrigine ranked lowest.

A Danish registry study of 20,967 women with bipolar disorder or epilepsy came out in 2026. It found that current valproate use was strongly linked to a new PCOS diagnosis, and the risk rose with more cumulative exposure. The authors say the findings support avoiding valproate in women of reproductive age when possible.

Is the risk higher if valproate is started at a young age?

The evidence points that way, but it comes mostly from epilepsy research. A 1993 Finnish study in the New England Journal of Medicine looked at 238 women with epilepsy. Of the women on valproate alone, 45% had menstrual disturbances and 43% had polycystic ovaries. Among women who started valproate before age 20, 80% had polycystic ovaries or hyperandrogenism.

A 2008 review on adolescents estimated that valproate induces PCOS features in about 7% of women overall. It said girls with epilepsy, and possibly bipolar disorder, seem especially susceptible. One proposed reason is that their hormone axis is still maturing. The Depakote label itself says counseling is especially important "for girls at the onset of puberty."

Keep in mind that bipolar disorder and epilepsy may each affect cycles on their own. That makes it harder to separate the drug effect from the illness. The STEP-BD design helped here by comparing valproate with other mood stabilizers in the same population.

Does weight gain play a role?

Weight gain and PCOS often travel together. MedlinePlus lists obesity, weight gain, or trouble losing weight among PCOS symptoms, along with irregular periods, extra facial or body hair, acne, and darkened skin patches. It also links PCOS to insulin resistance.

Valproate can cause weight gain. In the label's epilepsy trials, 9% of patients on high-dose valproate reported weight gain, compared with 4% on low dose. But weight is not the whole story. In the STEP-BD follow-up (below), menstrual problems improved after stopping valproate even though body weight did not change. For more on this side effect, see our guide to bipolar medications and weight gain.

Do the changes reverse after stopping Depakote?

Often, based on small studies. The STEP-BD team followed up women with valproate-linked PCOS features for a mean of 17 months. Of the four women who stopped valproate, three saw their PCOS reproductive features remit. All three who kept taking it still had them.

Among women whose features remitted, menstrual irregularity improved. Testosterone showed a trend toward lower levels. Body weight and the polycystic look of the ovaries on ultrasound did not change. The authors called this a preliminary report, and the numbers are very small.

Stopping a mood stabilizer is not a simple choice. Stopping suddenly can raise the risk of a mood episode. Any change should be planned with your prescriber. Our mood stabilizers guide compares the main options.

What does the label say for people who can become pregnant?

This is the most serious warning on the Depakote label. It carries a boxed warning for fetal risk. The label says valproate should not be used in women with bipolar disorder who are pregnant or planning pregnancy, or in any woman of childbearing potential, unless other medicines have failed or are otherwise unacceptable. If it is used, the label says to use effective contraception.

The label gives these numbers:

Spina bifida affects about 0.06 to 0.07% of births in the general population. With valproate exposure, the estimate is about 1 to 2%.
The North American AED Pregnancy Registry reported a major malformation rate of 9 to 11% with an average of 1,000 mg/day of valproate monotherapy.
In one cohort, children exposed to valproate before birth had a mean IQ of 97 at age 6, versus 105 to 108 with other seizure medicines.

The label also says estrogen-containing birth control may increase valproate clearance, so blood levels should be monitored when one is started or stopped. Irregular periods can make it harder to notice an early pregnancy, which is one more reason to track cycles. See our post on bipolar medications during pregnancy for the wider picture.

Mood symptoms tied to hormones can overlap with depression. If low mood is a big part of your picture, depression.md covers it in depth.

The bottom line

Depakote can cause irregular periods and PCOS features such as high testosterone, acne, and excess hair. In bipolar disorder, about 1 in 10 women on valproate developed this pattern in STEP-BD, usually within the first year. Starting young may raise the risk. Small studies suggest it often improves after stopping, but that choice belongs with your prescriber. Before you start, ask about a baseline cycle history and what to watch for. Report missed periods, new hair growth, or acne early.

Last updated: October 2026. This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change Depakote or any mood stabilizer without talking to your prescriber.